CD8A and cancer: Anti-PD1/PD-L1 treatment blocks the interaction between PD-L1 and PD1 and activates CD8+ T cells to kill cancer cells, which produces a promising antitumor effect; therefore, PD-L1 expression has been considered to be a predictive biomarker for response to anti-PD1 therapy [27].